Appili Therapeutics said Monday it will sponsor the first clinical trial in Canada evaluating Fujifilm Toyama Chemical’s drug Favipiravir for the prevention of COVID-19.
The Halifax company dedicated to fighting infectious diseases last November bought the rights to develop a new anti-fungal drug candidate from Fujifilm Toyama, and the announcement Monday shows the two companies are deepening their relationship.
Fujifilm Toyama will support the Phase 2 trials by providing supplies of Favipiravir, which is approved in Japan as the anti-influenza drug Avigan.
Appili has filed the clinical